Articles from AgelessRx

AgelessRx, a pioneer in longevity and telehealth solutions, has been selected as a Semi-Finalist in the landmark XPRIZE Healthspan competition. The first-of-its-kind longevity telehealth platform joins a select group of 40 global teams receiving Milestone 1 awarding of the $101 million, seven-year competition to extend healthy human healthspan by at least 10 years in adults aged 50–80, with a goal of 20 years, in one year or less. XPRIZE Healthspan is designed to spark bold scientific breakthroughs in healthy aging with the potential to benefit humanity at scale.

AgelessRx, a pioneer in longevity and telehealth solutions, announces the launch of its newest offering: Methylene Blue capsules. Recent studies suggest that Methylene Blue may support focus, brain health, and cellular energy production, all in a mess-free, convenient capsule format.

AgelessRx, a pioneer in longevity and telehealth solutions, announced the introduction of oral sublingual drops for GLP-1 receptor agonists Semaglutide and Tirzepatide. By offering non-injectable alternatives to medications that may support metabolic health management1 and counter the effects of aging2, AgelessRx continues to empower individuals to live longer, healthier lives.

AgelessRx, a pioneer in longevity and telehealth solutions, today announced its entry into the sleep health category, building on its commitment to redefine aging and improve quality of life. With a strong emphasis on research-backed solutions, AgelessRx’s sleep program provides personalized sleep treatment plans, and two new products–prescription Trazodone and natural, over-the-counter (OTC) Tran-Q Sleep Supplement–alongside easy-to-adopt lifestyle recommendations. Guided by the latest scientific insights into sleep health, AgelessRx sleep regimens are effective, tailored to customers’ unique needs, and integrated into holistic, personalized treatment plans focused on extending lifespan and enhancing healthspan.

AgelessRx, a leader in longevity telehealth solutions, announced the results of its 12-month, Participatory Evaluation of Aging with Rapamycin for Longevity (PEARL) clinical trial, the largest and longest decentralized, crowd-funded trial of its kind on Rapamycin safety for healthy aging in a normative aging population. The double-blind, randomized, placebo-controlled trial is also the first nationwide decentralized trial and the first large-scale intervention trial focused on healthy longevity outcomes.